Amunix: Sanofi Goes Big with $1 Billion Immuno-Oncology Buy
Under the terms of the deal, Sanofi is paying Amunix $1 billion up front and up to $225 million in various development milestone payments.
Read full article »
Amunix is a California-based biotechnology company that develops and markets T-cell and cytokine therapies for the treatment of cancer.
Read more